Engflag

Psyllogel

Quick links to important sections

Psyllogel

Psyllogel_CS

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Psyllogel

Psyllogel is an Over-The-Counter (OTC) therapeutic preparation primarily defined by its active component, Psyllium husk, which is classified as a Bulk-forming laxative. It is designed to support bowel regularity and optimize function within the alimentary tract via a physical, non-systemic mechanism of action.

Quick Facts: Psyllogel Identity

Property Description
Active ingredient Psyllium Husk (Ispaghula)
Form Granules or powder for oral suspension
Pharmacological class Bulk-forming laxative
Common use Supporting bowel regularity
Origin Natural origin, plant-derived (Plantago ovata)

What Type of Medicine is Psyllogel?

Psyllogel belongs to the pharmacological class of Bulk-forming laxatives, which are a category of Gastrointestinal Agents utilized to address chronic or occasional constipation. Psyllium acts as a fiber supplement that helps increase water content in the stool. This class is distinguished because its mechanism of action focuses on modifying the physical properties of the stool. The preparation's high-level purpose is to promote and maintain consistent, comfortable stool passage, often recommended for individuals who need to restore bowel regularity as part of managing their long-term digestive health.

The Composition and Natural Origin of Psyllium

The active ingredient in this product is Psyllium husk, which is also referred to by its common international nonproprietary name (INN) Ispaghula or its source plant's name, Plantago ovata. Psyllium husk is an indigestible, natural origin, plant-derived substance that constitutes the seed coat and is composed predominantly of mucilage and soluble fiber. Ispaghula husk serves as a bulk laxative for intestinal regulation, as the substance has the ability to regulate intestinal transit. The preparation is supplied for oral administration in the dosage form of granules or a fine powder, which must be mixed with a liquid vehicle prior to ingestion. Psyllogel is particularly known for offering different flavor profiles, which differentiates its brand positioning and patient acceptance compared to unflavored generic Psyllium formulations.

How Does Psyllogel Achieve Bowel Regularity?

Psyllogel supports bowel regularity through a primarily mechanical action that leverages the highly hydroscopic nature of the fiber. When introduced into the gastrointestinal tract with adequate fluid, the Psyllium fiber rapidly absorbs a substantial volume of water, which causes the material to swell, forming a viscous, gel-like mass. This physical change increases stool bulk and moisture content. The resulting bulky, soft mass provides a gentle distension that stimulates the intestinal walls, supporting natural peristalsis and facilitating the easier, non-irritating passage of fecal matter, which is its core general benefit for optimizing bowel function.

Regulatory References

  1. Psyllium: MedlinePlus Drug Information

What side effects are possible with Psyllogel?

Possible Side Effects and Safety Information

The safety profile for Psyllogel (Psyllium Husk) is characterized by adverse reactions classified primarily within the Gastrointestinal Disorders system, consistent with its non-systemic, bulk-forming action. The classifications and safety notes are based on official government regulatory documents.

Officially Documented Adverse Reactions

Classification System-Organ Class Examples Listed in Labeling
Common Gastrointestinal Disorders Flatulence, Abdominal Distension (Bloating)
Not Known Immune System Disorders Anaphylaxis, Hypersensitivity Reactions
Not Known Gastrointestinal Disorders Intestinal Obstruction, Fecal Impaction, Abdominal Cramps

The officially documented Common reactions, such as flatulence and abdominal distension, may sometimes occur during the first few days of treatment but are generally noted to diminish during continued use of the preparation. Severe allergic responses, including anaphylaxis, and events like oesophageal or intestinal obstruction are documented as serious potential adverse reactions, although their frequency is classified as Not Known.

Safety-Related Restrictions and Considerations

The medicine is restricted from use in individuals with existing high-level physical conditions, including confirmed Intestinal Obstruction, confirmed Fecal Impaction, or difficulty swallowing. Safety notes also indicate that the physical presence of the fiber may potentially decrease the rate of gastrointestinal absorption of concurrently administered oral medications, such as specific cardiac glycosides and coumarin derivatives. For special populations, use during pregnancy and lactation may be considered if dietary measures have proven insufficient, aligning with official guidelines for bulk-forming laxatives. Certain formulations may also contain phenylalanine, which is a safety consideration noted in official labeling for individuals with Phenylketonuria.

Overdose and Emergency Response

Overdose Manifestations and Complications

Overdose of Psyllium Husk is strictly related to its bulk-forming properties. Regulatory documents specify that an excessive dose may result in acute gastrointestinal symptoms, including abdominal discomfort, flatulence, and abdominal distension. A severe overdose, particularly one taken with inadequate fluid intake, can lead to life-threatening complications such as intestinal obstruction or esophageal obstruction and choking.

When to Seek Urgent Medical Help

Regulatory authorities mandate specific actions for suspected overdose or severe acute symptoms. If a person experiences chest pain, persistent vomiting, or difficulty in swallowing or breathing, the official instruction is to seek immediate medical attention. For any suspected overdose, regulatory labeling requires that a doctor or a Poison Control Center be contacted right away.

Overdose Management and Specific Risks

Since Psyllium Husk acts mechanically, the official management protocol is defined as symptomatic. The required supportive measure is to ensure adequate fluid intake is maintained. Population-specific warnings note that individuals with a history of difficulty swallowing or elderly patients are at a heightened risk for severe obstructive complications. No specific antidote is known or mentioned in regulatory documentation.

Therapeutic Uses of Psyllogel

What Psyllogel Treats: Main Uses and Benefits

Psyllogel is an Over-The-Counter therapeutic preparation used primarily to address functional irregularities within the gastrointestinal tract, focusing on symptoms and conditions where enhanced bulk and stool softening are needed. The active component, Psyllium, is considered relevant for easing symptoms related to constipation and is applied in domains where symptomatic support for stool volume and consistency is appropriate. This supportive product is applicable within clinical settings that involve the symptomatic management of chronic and occasional constipation.

This application is primarily relevant for easing groups of symptoms that may be associated with hard, dry stools and the functional strain of defecation. This supports the patient by assisting with the easier, non-irritating passage of fecal matter, which contributes to improved comfort during periods of heightened symptoms. It is also used in clinical scenarios like recovery after anorectal procedures or management of existing conditions like hemorrhoids and anal fissures.

Quick Fact: Support for Physical Discomfort

Symptom Domain Key Benefit
Hard, dry stools May assist with the easier, non-irritating fecal passage.
Straining/Irregularity Contributes to maintaining a sense of stability in bowel function.
Recurrent constipation May be part of symptomatic management for episodic manifestations.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Psyllogel?

The population eligibility for psyllium husk preparations, such as Psyllogel, is strictly governed by pre-existing health conditions and age, as defined by regulatory documents.

Eligibility Status Populations and Conditions
Contraindicated (Must Not Use) Known hypersensitivity to psyllium husk (Ispaghula). Patients with actual or potential intestinal obstruction (ileus), fecal impaction, or megacolon. Individuals with difficulty swallowing (dysphagia), diseases of the esophagus, or those presenting with unexplained abdominal pain, vomiting, or a sudden change in bowel habits persisting beyond two weeks. Use is also contraindicated in patients with difficult-to-regulate diabetes mellitus.
Use Restrictions/Caution Debilitated patients require medical supervision. Insulin-dependent diabetics using the product with meals may need medical consultation due to the potential effect on insulin requirements.
Age Group Eligibility Regulatory Statement
Adults and Adolescents (≥12 years) Approved for standard use.
Children (6 to <12 years) Use requires consultation with a doctor.
Children (Under 6 years) Not recommended due to insufficient data.

Use is generally considered acceptable during both pregnancy and lactation, as the active substance is not systemically absorbed by the body.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation confirms that the bulk-forming agent Psyllium Husk (Ispaghula) has documented interactions stemming from its physical, non-systemic effect in the gastrointestinal tract. These interactions necessitate specific administration rules and patient cautions.

Documented Interaction Patterns

The primary concern is a pharmacokinetic interaction where co-administration may delay or reduce the gastrointestinal absorption and systemic concentration of several oral medicinal products. Substances affected include Cardiac glycosides (e.g., Digoxin), Coumarin derivatives (e.g., Warfarin), Lithium, Carbamazepine, and Thyroid hormones (e.g., Levothyroxine). Absorption of Minerals (e.g., Iron) and certain Vitamins may also be reduced.

Administration and Cautions

To limit the impact on the absorption of concomitant therapy, regulatory labeling requires a mandatory separation interval.

Interaction Type Required Restriction
Timing Separation Must be taken at least 30 to 60 minutes before or after other oral medicines, with some labels advising a 2-hour interval.
Peristaltic Inhibitors Co-administration with drugs that inhibit gut movement, such as Opioids, is strongly cautioned due to a documented risk of gastrointestinal obstruction.
Antidiabetic Therapy Diabetic patients require medical supervision as the soluble fiber may contribute to a hypoglycemic effect, potentially requiring the adjustment of antidiabetic drug dosage.

Mechanism of Action

The action of Psyllogel (Psyllium Husk) is defined by a local, non-systemic mechanism involving the modulation of gastrointestinal physical dynamics, which triggers natural physiological reflexes and results in secondary metabolic effects.

Intraluminal Physical Dynamics and Viscosity Modulation

This domain addresses the drug's core local mechanism: its hydrophilic absorption of fluid within the GI lumen, leading to the formation of a viscous, hydrated gel. This physical process targets the luminal fluid and intestinal contents, significantly increasing the volume and moisture of the fecal mass. This action modifies the overall consistency of intestinal contents, which is a key physiological prerequisite for the subsequent modulation of intestinal motility.

Activation of the Peristaltic Reflex

The mechanical consequence of the increased bulk is a gentle distension of the colonic walls, which serves as a physiological mechanical stimulus for the enteric nervous system. This stimulation activates the natural peristaltic reflex, accelerating the coordination and frequency of gastrointestinal motility and reducing the transit time of contents through the colon. The mechanism thereby regulates the speed and coordination of contents through the propulsive reflex pathway.

Secondary Metabolic Modulation

Beyond its primary mechanical action, the highly viscous gel performs a secondary function by binding and sequestering bile acids within the small intestine. This sequestration interrupts the enterohepatic circulation of these compounds, increasing their fecal excretion. This effect indirectly modulates hepatic cholesterol metabolism by increasing the liver's demand to convert hepatic cholesterol for bile acid synthesis.

Dosage and Administration Information

Official Administration Guidelines for Psyllogel (Psyllium Husk)

The administration of Psyllogel, a preparation containing Psyllium Husk (Ispaghula), is based on established protocols. The primary and sole approved route of administration is oral, utilizing the product's powder or granular form.

Dosing and Preparation Protocol

The standard single dose for an adult is defined within the range of 3.5 g to 7 g of Psyllium Husk. The total daily intake, which is typically administered in one to three divided doses, must not exceed the maximum recommended 21 g. The regimen for adolescents (age 12 and older) is the same as the standard adult dose, while children aged 6 to 12 are instructed to use a reduced dose, often half the adult amount.

Administration is conditional on mandatory dilution. The measured dose must be thoroughly mixed with an adequate volume of liquid, typically between 150 mL and 240 mL of water or other fluid, and consumed immediately upon preparation. Ingestion of the product in its dry state or with insufficient fluid is restricted due to practical constraints related to its bulking mechanism. The administration should also not be performed just prior to reclining or going to sleep.

Use Patterns and Fluid Requirement

Psyllogel is designated for use in both short-term applications and as part of a long-term plan for maintaining bowel regularity. A critical procedural condition is the maintenance of sufficient overall daily fluid intake throughout the administration period, which supports the product's function. If an administration is missed, the next scheduled dose is taken as planned, without any dose doubling.

Recent Clinical Evidence

Evidence for Habitual and Chronic Constipation

Research into Psyllogel's active component, Psyllium husk (Ispaghula), has largely was studied for habitual and chronic constipation. This area of research was observed in numerous short-to-intermediate term Randomized Controlled Trials (RCTs) and comprehensive Meta-Analyses. These studies research examined large groups of adults to see how symptoms changed over time. The main outcomes research examined were objective measures like the number of Bowel Movements per week and detailed scoring of Stool Consistency using standardized scales. Patient-reported experiences, such as straining and the sensation of incomplete evacuation, were also applied in studies examining patient-reported experiences.

Findings describe patterns observed in the studies regarding the measured frequency of bowel movements; these patterns were observed in many studies. Some analyses studies report how symptoms evolved in terms of stool texture, and studies reported how symptoms evolved in terms of stool consistency in the observed populations. However, the majority of the reported outcomes were based on short-term observation periods, generally spanning a few weeks to a few months.

What remains uncertain is the full picture of long-term outcomes; limited information for long-term outcomes is available regarding the durability of observed changes beyond twelve weeks in major regulatory reviews. Furthermore, the evidence base includes studies of varying quality due to differences in patient groups and how the trials were set up. Data for the long-term patterns of use and adherence to fluid intake requirements are often limited.

Evidence for Conditions Requiring Softer Stools

Research has also explored Psyllium Husk in conditions where outcomes related to physical discomfort were monitored and where softening of stool was observed in studies examining related symptoms. This research examined populations with symptomatic conditions like hemorrhoids (piles) and anal fissures, and patients recovering after anorectal surgery. The research examined outcomes related to physical discomfort, such as pain and rectal bleeding, alongside the critical measure of stool consistency.

Studies described measurements of softer stool consistency, and findings describe patterns observed in the studies related to patient-assessed pain in some trials involving anorectal conditions. Reported findings suggest that the use of a bulk agent was associated with measurements of softer stool consistency. However, the evidence is limited compared to chronic constipation and is often drawn from smaller, older trials.

How should Psyllogel be stored and disposed of?

How to Store and Dispose of Psyllogel?

The storage and disposal of Psyllogel (Psyllium husk) are governed by specific regulatory requirements intended to maintain product stability and ensure environmental safety.

Storage Conditions

Requirement Details
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Container Integrity The container must be kept tightly closed and the product protected from moisture and humidity.
Child Safety The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Psyllogel must not be discarded into any plumbing system (e.g., sink or toilet). Disposal should be carried out strictly according to local regulations for unwanted medicines. This practice prevents potential environmental issues and product interference with wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Psyllogel found in:

A-Z Index: